Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30604113 | 1.00 | LMNA (0.42) | LMNAKDM4EPSMD14MAPTMEN1 | |
| SCHEMBL29681204 | 0.92 | LMNA (0.40) | LMNAKDM4EPSMD14MAPTMEN1 | |
| SCHEMBL24532735 | 0.92 | LMNA (0.40) | LMNAKDM4EPSMD14MAPTMEN1 | |
| SCHEMBL29681155 | 0.92 | LMNA (0.40) | LMNAKDM4EPSMD14MAPTMEN1 | |
| SCHEMBL24532840 | 0.92 | LMNA (0.40) | LMNAKDM4EPSMD14MAPTMEN1 | |
| SCHEMBL29090943 | 0.92 | LMNA (0.40) | LMNAKDM4EPSMD14MAPTMEN1 | |
| SCHEMBL30604218 | 0.92 | LMNA (0.40) | LMNAKDM4EPSMD14MAPTMEN1 | |
| SCHEMBL30604191 | 0.92 | LMNA (0.40) | LMNAKDM4EPSMD14MAPTMEN1 | |
| SCHEMBL24532317 | 0.92 | LMNA (0.43) | LMNAKDM4EPSMD14MAPTMEN1 | |
| SCHEMBL29681665 | 0.92 | LMNA (0.43) | LMNAKDM4EPSMD14MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101549-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | US | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| EP-4263535-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | Astrazeneca AB (SE) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-10-05 | — | — | US | disclosed |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-10-05 | — | — | US | disclosed |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-10-05 | — | — | US | disclosed |
| CN-116745291-A | N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide | 阿斯利康(瑞典)有限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022130270-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022130270-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101549-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, PREP, CTRL | LMNA 938/4885KDM4E 895/4885PSMD14 3531/4885 |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, PREP, CTRL | LMNA 938/4885KDM4E 895/4885PSMD14 3531/4885 |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | FAP, PREP, CTRL | LMNA 938/4885KDM4E 895/4885PSMD14 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.